Development of a PBPK model to quantitatively understand absorption and disposition mechanism and support future clinical trials for PB‐201

PB‐201 is the second glucokinase activator in the world to enter the phase III clinical trials for the treatment of type 2 diabetes mellitus (T2DM). Combined with the efficacy advantages and the friendly absorption, distribution, metabolism, and excretion characteristics, the indication population o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Miao, Lei, Zihan, Yu, Ziheng, Yao, Xueting, Li, Haiyan, Xu, Min, Liu, Dongyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349193/
https://www.ncbi.nlm.nih.gov/pubmed/37078371
http://dx.doi.org/10.1002/psp4.12964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349193/
https://www.ncbi.nlm.nih.gov/pubmed/37078371
http://dx.doi.org/10.1002/psp4.12964

Ejemplares similares